Pharma & Biotech Global Week in Review 11 Jan 2012 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

CAFC: “Revisionist history is unpersuasive,” but dissent raises issues in obviousness, preliminary injunction: Celsis v. Cellzdirect (IPBiz) (Patent Docs)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Pharmaceuticals and the world of IP – new book “Intellectual Property, Pharmaceuticals And Public Health Access to Drugs in Developing Countries” (IP tango)

Patent Docs tops stories of 2011 (#3 to #1 Patent Docs) (#6 to #4 Patent Docs) (#9 to #7 Patent Docs) (#12 to #10 Patent Docs)

Italy: Preliminary Technical Assessments not available to assess the validity of the patent: Novartis v. Crinos (Kluwer Patent Blog)

USPTO proposes to close post-notice of appeal gap in patent term adjustment rules (Pharma Patents)

US: CAFC affirms grant of permanent injunction in favour of Streck: Streck v Research Diagnostic (IPBiz)

US: CAFC: “Revisionist history is unpersuasive,” but dissent raises issues in obviousness, preliminary injunction: Celsis v. Cellzdirect (IPBiz) (Patent Docs)

US: A federal court win on the RLD theory of liability; more of Moore will likely be called for (FDA Law Blog)

US: “Size matters,” says FDA, when it comes to generic drug-RLD sameness (FDA Law Blog)

US: FDA issues draft guidance on medical device appeals processes (FDA Law Blog)

 

Products

ACTOplus met (Pioglitazone and Metformin) – US: Takeda files patent infringement suit against Mylan in reponse to Para IV challenge (Patent Docs)

Acular LS (Ketorolac tromethamine) – US: Allergan files patent infringement suit against Lupin in response to Para IV certification filing (Patent Docs)

Crestor (Rosuvastatin) – US: Pleading containing allegations of substantial noninfringing use sinks contributory infringement claim: Palmetto Pharmaceuticals v AstraZeneca Pharmaceuticals (Docket Report)

Levaquin (Levofloxacin) – Canada: Federal Court guidance on joinder and limitations: Janssen Inc v Teva Canada Ltd (Sufficient Description)

Mucinex (Guaifenesin) – US: Adams Respiratory Therapeutics, Inc. vs. Perrigo Co.- Dispute related to pharmacokinetic claim terms (IIPRD Blog)

Plavix (Clopidogrel) – Canada: Misleading affidavits – NOC proceedings and subsequent litigation (IPKat)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: